Compare Boston Scientific Corporation (BSX) vs The Coca-Cola Co K (KO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs The Coca-Cola Co K — how do they compare? Boston Scientific Corporation trades at $42.6 (market cap $66.37B), while The Coca-Cola Co K trades at $83.26 (market cap $357.45B). The key difference: The Coca-Cola Co K is far larger — about 5.4× Boston Scientific Corporation's market cap, and The Coca-Cola Co K pays a 2.55% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| BSX | KO | |
|---|---|---|
Market Cap | $66.37B | $357.45B |
Sector | Health | Consumer Staples |
52-Week High | $108.14 | $84.25 |
52-Week Low | $42.63 | $65.67 |
Enterprise Value | $75.94B | $387.52B |
Volume | — | 14,630,257 |
Dividend Yield | — | 2.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
Coca-Cola (KO) trades at $84.25, up 0.91% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 27.8% net margin and 45.8% ROE, though valuation multiples like P/E of 26.5 appear elevated. Recent news highlights institutional buying and stable demand trends ahead of Q2 earnings.
The outlook remains positive with a $89.75 analyst target suggesting 6.5% upside, supported by dividend reliability. Key risks include high debt levels and regional demand volatility. The stock presents a steady growth opportunity with moderate upside potential balanced by valuation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About The Coca-Cola Co K
The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →
